What Guardant Health (GH) Said on Its Q3 Earnings Call
Guardant Health (GH) reported Q3 earnings, with oncology revenue up 25% to $231M and test volume rising 58%. Shield's average selling price was above $800, with expectations of short-term decline. The company maintained its 2026 outlook for 30% oncology revenue growth and now expects over 50% volume growth. Non-GAAP gross margin improved to 67%, and adjusted EBITDA loss narrowed to $37M. Guardant also highlighted FDA approvals and plans for new product launches.
How this was made
The 30-second read
Why it matters
The earnings release provides fresh data on revenue, volume, and cost metrics, shaping short‑term price expectations.
Market read
The earnings beat on revenue but higher cash‑burn guidance creates a nuanced outlook, likely prompting modest volatility.
What to watch
Potential reimbursement improvements from CMS coding changes in early 2027 could materially improve cash flow beyond current guidance.
Background
Guardant Health reported Q3 results, highlighting oncology revenue growth, new FDA approval, and updated cash‑burn guidance.
Ticker impact
Q3 earnings disclosed revenue, volume growth, updated oncology revenue guidance and increased cash‑burn guidance, plus new FDA approval and cost reductions for Shield.
potential downside as investors price in higher cash‑burn and slower free‑cash‑flow outlook
Guidance lift for oncology revenue is positive, yet the upward revision to cash‑burn and slower cost reductions introduce execution risk, likely leading to modest short‑term pressure.
Market effects
Strong oncology volume growth may benefit other liquid biopsy and precision‑medicine peers.
U.S. healthcare investors may see a shift in coverage expectations for blood‑based cancer tests.
FDA approval of Guardant360 CDx could set a precedent for companion diagnostics worldwide.
Counterpoint
If the cost‑reduction trajectory accelerates faster than guidance suggests, the stock could rally on margin expansion.
Key entities
- CompanyGuardant Health
Precision oncology firm reporting Q3 earnings.
- CompanyAstraZeneca
Partner for FDA‑approved Guardant360 CDx companion diagnostic.
